Previous studies suggested small molecule kinase inhibitors of RIP2 presented benefits in animal models of multiple sclerosis [28, 29] and Crohn’s disease-like ileitis [30], positioning RIP2 as a promising target against human inflammatory diseases. This evidence concerns the gene RIPK2 and Crohn disease.